Development Versus Dealmaking: How To Obtain A Blockbuster

Most of the companies with blockbuster drugs approved over the past decade oversaw their clinical development internally. Lilly holds the lead with eight blockbusters developed in-house.  

Discovery Versus Dealmaking
• Source: Shutterstock

Considering that an actual or potential blockbuster developed by a smaller biotech is catnip to big pharma, obtaining a blockbuster by buying it might be expected to be the most common strategy. But according to data from Evaluate, only 81 companies with blockbusters gained them through dealmaking – at least when the parameters are limited to clinical stages.

Meanwhile, 105 drug companies either discovered blockbusters internally or bought them before clinical trials had started. Many companies that developed...

More from Business Strategy

More from In Vivo

EU Medtech Outlook: The View From MedTech Europe Experts

 
• By 

MedTech Forum 2025 was less MDR-focused than in previous years, as macro issues and exogenous threats were forced further into the center of medtech business thinking.

‘Confident In Lorundrostat’s Promise’: Mineralys CEO Talks Trials And Next Steps

 

In a conversation with In Vivo, CEO Jon Congleton discusses Mineralys’s data-rich journey toward an NDA filing, the significance of recent trial wins and how its candidate may offer a dual benefit in blood pressure and renal protection.

BioBytes: Qubit Pharmaceuticals Unveils Quantum AI Model For Drug Discovery

 
• By 

Qubit Pharmaceuticals and Sorbonne University launched a quantum AI model that could slash drug synthesis requirements and enable exploration of previously undruggable targets.